Dianthus Therapeutics, Inc. /DE/ SEC filings DNTH

Dianthus Therapeutics, Inc. /DE/ has 658 filings in SEC EDGAR's recent list, going back to Nov 23, 2016. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Dianthus Therapeutics, Inc. /DE/ SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 4, 2026 Nov 4, 2026
SCHEDULE 13G Ownership over 5% (passive) Oct 30, 2026 —
4 Insider transaction Sep 18, 2026 Sep 17, 2026
S-3ASR Automatic shelf registration Sep 18, 2026 —
144 Notice of proposed sale Sep 17, 2026 —
4 Insider transaction Sep 3, 2026 Sep 1, 2026
144 Notice of proposed sale Sep 1, 2026 —
4 Insider transaction Aug 19, 2026 Aug 19, 2026
4 Insider transaction Aug 14, 2026 Aug 13, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 13, 2026 —
4 Insider transaction Aug 11, 2026 Aug 10, 2026
4 Insider transaction Aug 11, 2026 Aug 10, 2026
4 Insider transaction Aug 11, 2026 Aug 7, 2026
144 Notice of proposed sale Aug 10, 2026 —
144 Notice of proposed sale Aug 10, 2026 —
144 Notice of proposed sale Aug 10, 2026 —
4 Insider transaction Aug 7, 2026 Aug 7, 2026
144 Notice of proposed sale Aug 7, 2026 —
144 Notice of proposed sale Aug 7, 2026 —
144 Notice of proposed sale Aug 7, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 7, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 7, 2026 —
10-Q Quarterly report Aug 4, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 4, 2026 Aug 4, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 28, 2026 —
4 Insider transaction Jul 13, 2026 Jul 9, 2026
144 Notice of proposed sale Jul 9, 2026 —
4 Insider transaction Jun 18, 2026 Jun 17, 2026
144 Notice of proposed sale Jun 17, 2026 —
8-K Current report
Other events
Jun 12, 2026 Jun 12, 2026
4 Insider transaction Jun 2, 2026 Jun 1, 2026
144 Notice of proposed sale Jun 1, 2026 —
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
4 Insider transaction May 22, 2026 May 21, 2026
8-K Current report
Shareholder vote results
May 22, 2026 May 21, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G Ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 14, 2026 —
4 Insider transaction May 11, 2026 May 8, 2026
10-Q Quarterly report May 5, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 5, 2026 May 5, 2026
SCHEDULE 13G Ownership over 5% (passive) Apr 27, 2026 —
4 Insider transaction Apr 10, 2026 Apr 9, 2026
144 Notice of proposed sale Apr 9, 2026 —
ARS Annual report to shareholders Apr 9, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 9, 2026 —
DEF 14A Proxy statement Apr 9, 2026 May 21, 2026
4 Insider transaction Apr 1, 2026 Mar 31, 2026
4 Insider transaction Apr 1, 2026 Mar 31, 2026
144 Notice of proposed sale Mar 31, 2026 —
144 Notice of proposed sale Mar 31, 2026 —
4 Insider transaction Mar 26, 2026 Mar 24, 2026
8-K Current report
Other events
Mar 26, 2026 Mar 26, 2026
144 Notice of proposed sale Mar 24, 2026 —
4 Insider transaction Mar 17, 2026 Mar 16, 2026
4 Insider transaction Mar 13, 2026 Mar 12, 2026
4 Insider transaction Mar 13, 2026 Mar 12, 2026
4 Insider transaction Mar 13, 2026 Mar 12, 2026
144 Notice of proposed sale Mar 12, 2026 —
144 Notice of proposed sale Mar 12, 2026 —
144 Notice of proposed sale Mar 12, 2026 —
8-K Current report
Material agreement
Mar 12, 2026 Mar 10, 2026
424B5 Prospectus supplement Mar 11, 2026 —
S-3MEF Filing Mar 10, 2026 —
424B5 Prospectus supplement Mar 9, 2026 —
S-8 Employee stock plan registration Mar 9, 2026 —
10-K Annual report Mar 9, 2026 Dec 31, 2025
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Mar 9, 2026 Mar 9, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
4 Insider transaction Feb 4, 2026 Feb 3, 2026
4 Insider transaction Feb 4, 2026 Feb 3, 2026
4 Insider transaction Feb 4, 2026 Feb 3, 2026
4 Insider transaction Feb 4, 2026 Feb 3, 2026
4 Insider transaction Feb 4, 2026 Feb 3, 2026
EFFECT Filing Jan 30, 2026 —
CORRESP Letter to the SEC Jan 29, 2026 —
UPLOAD Letter from the SEC Jan 29, 2026 —
S-3 Shelf registration Jan 28, 2026 —
8-K Current report
Results of operations, Regulation FD disclosure
Jan 12, 2026 Jan 12, 2026
4 Insider transaction Dec 5, 2025 Dec 4, 2025
144 Notice of proposed sale Dec 4, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 25, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 19, 2025 —
4 Insider transaction Nov 14, 2025 Nov 13, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
144 Notice of proposed sale Nov 13, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Nov 12, 2025 —
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 5, 2025 Nov 5, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 5, 2025 —
8-K Current report
Other events
Nov 3, 2025 Nov 3, 2025
8-K Current report
Material agreement, Results of operations, Other events
Oct 16, 2025 Oct 16, 2025
4 Insider transaction Oct 3, 2025 Sep 30, 2025
4 Insider transaction Sep 25, 2025 Sep 23, 2025
4 Insider transaction Sep 25, 2025 Sep 23, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 15, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Sep 12, 2025 —
4 Insider transaction Sep 11, 2025 Sep 9, 2025
8-K Current report
Material agreement
Sep 11, 2025 Sep 9, 2025
424B5 Prospectus supplement Sep 11, 2025 —
144 Notice of proposed sale Sep 9, 2025 —
424B5 Prospectus supplement Sep 8, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Sep 8, 2025 Sep 8, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
4 Insider transaction May 22, 2025 May 22, 2025
4 Insider transaction May 22, 2025 May 22, 2025
4 Insider transaction May 22, 2025 May 22, 2025
4 Insider transaction May 22, 2025 May 22, 2025
4 Insider transaction May 22, 2025 May 22, 2025
4 Insider transaction May 22, 2025 May 22, 2025
3 Initial insider ownership May 22, 2025 May 22, 2025
8-K Current report
Officer or director change, Shareholder vote results
May 22, 2025 May 22, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
SCHEDULE 13G Ownership over 5% (passive) May 15, 2025 —
10-Q Quarterly report May 12, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 12, 2025 May 12, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 12, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 24, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Apr 17, 2025 —
ARS Annual report to shareholders Apr 10, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 10, 2025 —
DEF 14A Proxy statement Apr 10, 2025 May 22, 2025
SCHEDULE 13G Ownership over 5% (passive) Mar 24, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Mar 19, 2025 —
S-8 Employee stock plan registration Mar 11, 2025 —
10-K Annual report Mar 11, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 11, 2025 Mar 11, 2025
4 Insider transaction Mar 5, 2025 Mar 4, 2025
3 Initial insider ownership Mar 5, 2025 Mar 4, 2025
8-K Current report
Officer or director change
Mar 5, 2025 Mar 4, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 5, 2025 —
4 Insider transaction Feb 4, 2025 Feb 3, 2025
4 Insider transaction Feb 4, 2025 Feb 3, 2025
4 Insider transaction Feb 4, 2025 Feb 3, 2025
4 Insider transaction Feb 4, 2025 Feb 3, 2025
4 Insider transaction Feb 4, 2025 Feb 3, 2025
8-K Current report
Other events
Dec 12, 2024 Dec 12, 2024
SC 13D/A Amended ownership over 5% (active) Dec 3, 2024 —
SC 13G Ownership over 5% (passive) Nov 22, 2024 —
SC 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
SC 13G Ownership over 5% (passive) Nov 8, 2024 —
10-Q Quarterly report Nov 7, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 7, 2024 Nov 7, 2024
SC 13G Ownership over 5% (passive) Oct 24, 2024 —
RW Filing Oct 21, 2024 —
424B5 Prospectus supplement Oct 11, 2024 —
SC 13G Ownership over 5% (passive) Oct 11, 2024 —
424B3 Prospectus Oct 11, 2024 —
EFFECT Filing Oct 9, 2024 —
EFFECT Filing Oct 9, 2024 —
CORRESP Letter to the SEC Oct 7, 2024 —
CORRESP Letter to the SEC Oct 7, 2024 —
UPLOAD Letter from the SEC Oct 7, 2024 —
UPLOAD Letter from the SEC Oct 7, 2024 —
4 Insider transaction Oct 1, 2024 Sep 27, 2024
S-3 Shelf registration Oct 1, 2024 —
S-3 Shelf registration Oct 1, 2024 —
4 Insider transaction Sep 18, 2024 Sep 16, 2024
3 Initial insider ownership Sep 18, 2024 Sep 16, 2024
424B3 Prospectus Sep 16, 2024 —
8-K Current report
Officer or director change
Sep 16, 2024 Sep 16, 2024
SC 13D/A Amended ownership over 5% (active) Sep 12, 2024 —
S-8 Employee stock plan registration Aug 8, 2024 —
424B3 Prospectus Aug 8, 2024 —
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
8-K Current report
Regulation FD disclosure
Jun 6, 2024 Jun 6, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024
4 Insider transaction May 28, 2024 May 23, 2024

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DNTH (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1690585
Former names
Magenta Therapeutics, Inc. (until Sep 8, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.